LAMA (Long-Acting Muscarinic Antagonists) Bronchodilators for COPD

In this lecture from This is Why, Dr. Busti will explain the COPD maintenance inhalers you’ll actually see in practice. In this pharmacology review, we break down LAMA (long-acting muscarinic antagonist) bronchodilators—one of the most important bronchodilator classes for COPD treatment—so you can confidently understand the drugs, the mechanism, and the real-world clinical use.You’ll learn how to:What LAMA / antimuscarinic bronchodilators are and how they workWhere LAMA inhalers fit in COPD therapy and long-term symptom controlKey differences and practical pearls for common COPD inhalersHigh-yield side effects, contraindications, and patient counseling pointsHow to recognize and avoid common med errors and confusion with inhaler names/classesDrugs covered:Tiotropium (Spiriva)Umeclidinium (Incruse Ellipta)Aclidinium (Tudorza Pressair)Glycopyrrolate (COPD maintenance formulations)The goal = make medical education easy and clinically relevant.Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/lama-bronchodilators-copd-tiopotropium-umeclidinium-pharmacologyGet more with a free membership at https://www.thisiswhy.health/Access free downloads from our videos Access deep dive content from Dr. BustiOrganize content via playlists & collectionsJoin live Q&AReceive member newslettersCoupons & discounts for exam prep resourcesIf this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!Disclaimer:This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.